RxDoctor Payments Data

John Dowd, DO

Gastroenterology · Manchester, NHNPI 1164498648

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,058 of the $3,474 with a category attached, or 88.0%. 18 manufacturers reported payments, led by AbbVie at 26.1% of the total.

$3,474in general payments, 2019–2025

Across 111 payments — averaging $31.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$907
  • Olympus Corporation Of The Americas$435
  • Bristol Myers Squibb$434
  • Johnson & Johnson$388
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$319
  • Madrigal Pharmaceuticals$194
  • plus $797 from 12 others

What the payments were for

  • Travel & lodging$41612%
  • Food & beverage$3,05888%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,474 in reported general payments places this provider in the 80th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$104,306
Medicare patients
432
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$47,875
LinzessLinaclotide37$27,920
Mesalamine21$13,330
Ursodiol34$8,388
SutabSod Sulf/Pot Chloride/Mag Sulf34$5,529
Balsalazide Disodium23$2,596
Omeprazole107$1,471
Ondansetron Hcl15$1,218
Colestipol Hcl12$1,110
Pantoprazole Sodium49$933
Azathioprine21$582
Famotidine14$327
Dicyclomine Hcl16$276
Amitriptyline Hcl13$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$907$75,79549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →